<i>Mtb</i> infection resulted in a decrease in macrophage and CD4+ T cell number. by Nidhi Kapoor (290320)

Parasite Load Decrease during Application of a Safe and Easily Applied Antileishmanial Aminoglycoside Cream by Afif Ben Salah (202439)

Blocking the translation of swiprosin-1 with siRNA and decreasing the intracellular calcium with Bapta-AM attenuated spreading in ARVC. by Franziska Nippert (3589883)

Influenza A virus infection leads to a time-dependent decrease of lung cDCs and DC progenitors in the BM. by Ranin Beshara (5905115)

(a) M-K test of annual average water level in Caspian Sea (unformatted fit (UF) and underidentification bias (UB) is positive and reverse order in the time series respectively; ɑ i... by Zihao Duan (17403792)

CDK2/Speedy A localization in <i>Cdk2</i>^<i>T160A</i> spermatocytes. by Nathan Palmer (264897)

“…Percentages of mid-pachytene–stage nuclei with at least one telomere showing a decrease in telomeric CDK2 intensity of ≥50% (as compared with the average telomeric CDK2 intensity for that cell) are quantified in panel O. …”

GASP mutants initially reach a high population density and subsequently decrease population viability. by Felix J. H. Hol (475373)

DOX decreases body mass gain over time in a sub-chronic toxicity model. by Gonçalo C. Pereira (156673)

A possible explanation for a nonlinear decline in populations could be a decrease in active AMP concentration over time due to degradation. by Alexandro Rodríguez-Rojas (326213)

Figure 2. Decrease in contrast with age. by Aurélie Porcheron (385827)

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial by Michel Mandro (2637532)

“…<div><p>Introduction</p><p>Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a randomized clinical trial to assess whether ivermectin treatment decreases seizure frequency.…”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Average changes in (A) spontaneous AP firing rate, (B) ATP and (C) cAMP by decreasing CaMKII activity with KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L). by Yael Yaniv (162548)

FSS rescues homocysteine-caused the decrease of NO production in cultured HUVECs after the application of A23187. by Cathy W. C. Bi (108697)

Heart specific RNase Z variants show a mild decrease in longevity and locomotor response. by Ekaterina Migunova (15909887)